Lenalid 10mg capsule is an anticancer medicine used for multiple myeloma & myelodysplastic syndrome. It enhances immune system to attack abnormal cancer cells & prevents the growth of new blood vessels within the tumor. It activates the immune system and facilitates immune-mediated destruction of cancer cells. Lenalid 10mg Capsule is a prescription medication can be taken once daily (exact schedule depends on disease type. Lenalid 10mg contains Lenalidomide used to treat certain blood cancers & bone marrow disorders, including multiple myeloma, myelodysplastic syndromes (MDS), mantle cell lymphoma, and some forms of follicular lymphoma.. It activates the immune system and facilitates immune-mediated destruction of cancer cells to slow down the growth and multiplication of abnormal cells. It Prevents tumors from developing new blood vessels (anti-angiogenic effect)
Lenalid 10mg capsules, contains Lenalidomide, help treat certain blood cancers & bone marrow disorders by enhancing the immune system and reducing cancer cell growth.
Multiple myeloma is the primary indication treated using Lenalid 10 mg. It refers to the uncontrollable cell division of plasma cells in the bone marrow. This leads to abnormal protein production, bone damage, and weakened immunity. Lenalid 10 mg works by controlling the growth and spread of cancer cells, specifically, by facilitating immune-mediated destruction of cancer cells.
Myelodysplastic syndromes are a group of disorders characterized by the inability of the bone marrow to produce healthy and functional plasma cells. These cells are ineffective and die early. As a result, symptoms like anemia (fatigue, weakness), low white cells (infections), and low platelets (bleeding tendency) are observed in patients with this syndrome. Lenalid 10 mg is used for this condition as it can improve the production of red blood cells, while also targeting the abnormal cells in the bone marrow.
Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma that arises from the B-lymphocytes in the lymph nodes. In advanced stages, this disorder can spread to the spleen, bone marrow, and sometimes the gastrointestinal tract. Lenalid 10 mg helps by inhibiting the multiplication of the malignant B-lymphocytes.
This type of cancer grows slowly in the lymph nodes of the B-lymphocytes. This tumor starts with painless swelling of the lymph nodes and remains largely asymptomatic. However, after reaching an advanced stage, it transforms into a more aggressive type of lymphoma. For this disorder, Lenalid 10 mg boosts the immune attack on cancer cells and reduces the growth and proliferation of cancer cells.
Lenalid 10 mg, which consists of the active ingredient Lenalidomide, is an immunotherapeutic agent and anti-cancer medication that is primarily used in the treatment of multiple myeloma and some types of lymphoma. These cancers often involve the uncontrolled growth of abnormally functioning immune cells or bone marrow cells, which evade normal cell death and create an environment that allows cancerous masses (tumors) to develop and continue to thrive.
First, Lenalidomide binds to a protein called cereblon (CBL), which alters the activity of the intracellular pathways and degradation of two major transcription factors required for survival of malignant cells. As a result, there is reduced proliferation and increased programmed cell death (i.e., apoptosis) of cancer cells. Additionally, Lenalidomide stimulates the immune system by enhancing the activity of T lymphocytes and natural killer (NK) cells, thereby increasing their ability to identify and kill cancer cells.
First, Lenalidomide binds to a protein called cereblon (CBL), which alters the activity of the intracellular pathways and degradation of two major transcription factors required for survival of malignant cells. As a result, there is reduced proliferation and increased programmed cell death (i.e., apoptosis) of cancer cells. Additionally, Lenalidomide stimulates the immune system by enhancing the activity of T lymphocytes and natural killer (NK) cells, thereby increasing their ability to identify and kill cancer cells.
Lenalid 10 mg has an anti-angiogenic effect and prevents the formation of new blood vessels, thereby depriving the tumor of vital nutrients and oxygen. Finally, this medication decreases the levels of inflammatory cytokines that promote tumor growth. By suppressing tumor growth, enhancing important immune responses, and disrupting supporting systems for tumors, Lenalid 10 mg helps prevent disease progression and extend the duration of remission.
Respiratory
Lenalid 10 mg is used to treat multiple myeloma and certain lymphomas.
Yes. There is a DVT/PE risk associated with this drug.
The tablet should be swallowed whole with water.
Alcohol consumption must be avoided while on Lenalidomide therapy.
The treatment duration will be decided by healthcare providers.
